Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CHKA | P35790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4985800 | 0.75 | — | — | |
| SCHEMBL3913614 | 0.73 | GNAI3 (0.33) | — | |
| SCHEMBL4986702 | 0.72 | LMNA (0.39) | — | |
| Iodide SCHEMBL29124171 | 0.72 | LMNA (0.34) | — | |
| Hydrochloric Acid SCHEMBL28556911 | 0.70 | LMNA (0.38) | — | |
| SCHEMBL25720922 | 0.69 | — | — | |
| SCHEMBL4984203 | 0.68 | FAAH (0.31) | — | |
| SCHEMBL14450380 | 0.67 | — | — | |
| SCHEMBL8441641 | 0.63 | — | — | |
| SCHEMBL14881405 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012149093-A1 | 2-GUANIDINO-4-OXO-IMIDAZOLINE DERIVATIVES AS ANTIMALARIAL AGENTS, SYNTHESIS AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF ARMY (US) | 2012-11-01 | — | — | WO | disclosed |
| EP-2495245-A2 | GRAM-POSITIVE CARBAPENEM ANTIBACTERIALS AND PROCESSES FOR THEIR PREPARATION | FOB Synthesis, Inc. (US) | 2012-09-05 | — | — | EP | disclosed |
| CN-101362725-B | Method for preparing tetramethylpyrazine guanidine derivatives and application thereof | UNIV SHANDONG | 2010-07-21 | — | — | CN | disclosed |
| US-20100075945-A1 | GRAM-POSITIVE CARBAPENEM ANTIBACTERIALS AND PROCESSES FOR THEIR PREPARATION | CHOI WOO-BAEG | 2010-03-25 | — | — | US | disclosed |
| US-7632828-B2 | Gram-positive carbapenem antibacterials and processes for their preparation | FOB SYNTHESIS, INC. (US) | 2009-12-15 | — | — | US | disclosed |
| EP-1765821-A4 | GRAM-POSITIVE CARBAPENEM ANTIBACTERIALS AND PROCESSES FOR THEIR PREPARATION | FOB SYNTHESIS INC (US) | 2009-05-20 | — | — | EP | disclosed |
| CN-101362725-A | Method for preparing tetramethylpyrazine guanidine derivatives and application thereof | UNIV SHANDONG (CN) | 2009-02-11 | — | — | CN | disclosed |
| EP-1765821-A2 | GRAM-POSITIVE CARBAPENEM ANTIBACTERIALS AND PROCESSES FOR THEIR PREPARATION | FOB Synthesis, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060074070-A1 | Gram-positive carbapenem antibacterials and processes for their preparation | FOB SYNTHESIS, INC. | 2006-04-06 | — | — | US | disclosed |
| WO-2005123069-A2 | GRAM-POSITIVE CARBAPENEM ANTIBACTERIALS AND PROCESSES FOR THEIR PREPARATION | FOB SYNTHESIS, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074070-A1 | Gram-positive carbapenem antibacterials and processes for their preparation | MGAM, GSK3B, GSK3A | CA2 1051/4885CA12 1516/4885CA1 3339/4885 |
| US-20100075945-A1 | GRAM-POSITIVE CARBAPENEM ANTIBACTERIALS AND PROCESSES FOR THEIR PREPARATION | MGAM, GSK3B, GSK3A | CA2 1051/4885CA12 1516/4885CA1 3339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.